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Introduction
Patients with type 2 diabetes are frequently main-
tained in poor glycaemic control for prolonged peri-
ods, increasing the risk of serious complications (1).
Insulin is the most effective therapy to achieve gly-
caemic goals in these patients (2), yet there is reluc-
tance among patients and physicians to initiate
insulin (3).
Contributors to patient reluctance to initiate insu-
lin include concerns about side effects, desire to
avoid injections, feelings of personal failure and
skepticism about insulin’s effectiveness (3–5). Less is
known about the factors that contribute to physician
reluctance to initiate insulin in patients with type 2
diabetes. Riddle (6) observed patterns of insulin
usage in the USA and found little consensus among
medical practitioners regarding when insulin therapy
should be initiated. He proposed that some providers
were reluctant to prescribe insulin to patients with
type 2 diabetes because of both theoretical concerns
(hypoglycaemia, weight gain and the belief that insu-
lin has negative metabolic effects) and practical con-
cerns (patient anxiety about insulin, patient cognitive
abilities and the complexity of training patients to
administer insulin). Riddle noted that diabetes spe-
cialists tended to be more aggressive than primary
care physicians (PCPs) with insulin initiation in
patients with type 2 diabetes.
The Diabetes Attitude Wishes and Needs study
(3), a large multinational survey of physicians and
patients, indicated that US physicians were signiﬁ-
cantly more disposed to delay insulin therapy than
physicians in most other countries. The results also
indicated that diabetes specialists are less inclined
than PCPs to delay insulin initiation. A recent US
survey of diabetes specialists and academic generalists
showed that specialists reported no major barriers to
initiating insulin treatment in patients with type 2
diabetes, but the majority of academic generalists
indicated several patient-derived barriers (e.g.
patients’ fear of insulin) (7).
SUMMARY
Background: Insulin is the most effective drug available to achieve glycaemic
goals in patients with type 2 diabetes. Yet, there is reluctance among physicians,
speciﬁcally primary care physicians (PCPs) in the USA, to initiate insulin therapy in
these patients. Aims: To describe PCPs’ attitudes about the initiation of insulin in
patients with type 2 diabetes and identify areas in which there is a clear lack of
consensus. Methods: Primary care physicians practicing in the USA, seeing 10 or
more patients with type 2 diabetes per week, and having > 3 years of clinical
practice were surveyed via an internet site. The survey was developed through lit-
erature review, qualitative study and expert panel. Results: Primary care physi-
cians (n = 505, mean age = 46 years, 81% male, 62% with > 10 years practice;
52% internal medicine) showed greatest consensus on attitudes regarding
risk⁄beneﬁts of insulin therapy, positive experiences of patients on insulin and
patient fears or concerns about initiating insulin. Clear lack of consensus was seen
in attitudes about the metabolic effects of insulin, need for insulin therapy, ade-
quacy of self-monitoring blood glucose, time needed for training and potential for
hypoglycaemia in elderly patients. Conclusions: The beliefs of some PCPs are
inconsistent with their diabetes treatment goals (HbA1c £ 7%). Continuing medical
education programmes that focus on increasing primary care physician knowledge
about the progression of diabetes, the physiological effects of insulin, and tools for
successfully initiating insulin in patients with type 2 diabetes are needed.
What’s known
Insulin is the most effective drug available to
achieve glycaemic goals in patients with type 2
diabetes, yet there is reluctance among many
physicians to initiate insulin therapy in these
patients. Diabetes specialists tend to be more
aggressive than primary care physicians (PCPs) with
insulin initiation in patients with type 2 diabetes,
and US physicians are more disposed to delay
insulin than physicians in other countries.
What’s new
This article conﬁrms that US PCPs lack consensus
on some beliefs about insulin initiation. Consensus
was seen regarding insulin risk ⁄ beneﬁts, positive
patient experiences of insulin and patient fears
about initiating insulin. No consensus was seen
regarding insulin’s metabolic effects, need for
insulin, adequacy of self-monitoring blood glucose,
time needed for training and potential for
hypoglycaemia in elderly patients. Some PCPs have
beliefs inconsistent with their diabetes treatment
goals (HbA1c £ 7%).
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physicians’ attitudes about initiating insulin in
patients with type 2 diabetes, they did not include
PCPs, who care for the majority of patients with type
2 diabetes in the USA (8).
This study aimed to describe the attitudes of US
PCPs regarding initiating insulin in patients with type
2 diabetes and addresses these research questions:
• Is there consensus among PCPs on some beliefs
about insulin initiation; if so, which ones?
• Is there lack of consensus among PCPs on some
beliefs about insulin initiation; if so, which ones?
• Are there associations between PCP characteristics
(such as age, years of practice, etc.) and beliefs about
insulin therapy?
Methods
Study participants
Study participants were sampled from the physician
panel of Harris Interactive, a large market research
ﬁrm. The panel consists of more than 40,000 US
physicians, is representative of the general US physi-
cian population and includes more than 40 medical
specialties and several subspecialties. Physician names
are continuously updated and authenticated against
the American Medical Association (AMA) master
ﬁle. Panel membership is voluntary; physicians may
unsubscribe at anytime. To qualify for the study,
physicians were required to have > 3 years of clinical
practice experience and to treat > 10 patients with
type 2 diabetes per week.
Physician survey development
The physician survey included a demographic assess-
ment, a question about glycaemic goals for three
patient age groups, and 30 belief items beginning
with ‘I believe…’. For the belief items, respondents
were asked to indicate on a ﬁve-point Likert-type
scale ranging from one, ‘strongly disagree’, to ﬁve,
‘strongly agree’, the extent to which they agreed with
the statements presented.
Item development for the survey was based on a
review of the literature on physician barriers to initi-
ating insulin in patients with type 2 diabetes (3,6,9),
a pilot study of web-based case studies (10), results
of an online asynchronous focus group (in which
participants log on at their convenience) of 15 PCPs
(unpublished data, 2005), and the input of an expert
panel [two PCPs and two authors of the Diabetes
Attitude Scale (RMA, JTF)] (11). Items were categor-
ised a priori as beliefs about insulin as an injection,
metabolic effect of insulin, risk⁄beneﬁt of insulin,
perceived concerns about insulin therapy of patients
on oral therapy, perceived experiences of patients on
insulin therapy, appropriate timing for insulin ther-
apy initiation, and the training and resources needed
for insulin therapy initiation. Some items were
worded with the expectation that most PCPs would
agree with the statement, others with the expectation
that most PCPs would disagree with the statement.
Survey recruitment and administration
Harris Interactive ﬁelded the online survey from 19
December 2005 to 21 December 2005. Email invita-
tions were sent to 2552 physicians board certiﬁed in
Family Practice, General Practice or Internal Medi-
cine. Recipients were offered a $60 honorarium or
the option to donate the honorarium to a charity of
the recipient’s choice upon qualifying for and com-
pleting the survey before the quota of responses (505
responses, determined by the funding available for
the honoraria with an approximately equal represen-
tation of internal medicine and family practice physi-
cians) was ﬁlled. The survey was accessible to invited
physicians until the quota was ﬁlled. Of the 982 phy-
sicians (39% of the recipients) who responded to the
invitation, 505 (51%) qualiﬁed for and completed
the survey, 70 (7%) did not qualify, and 407 (41%)
qualiﬁed after the quota had been met and did not
complete the survey.
Statistical analysis
Frequency distributions were calculated for all survey
items. To determine beliefs about which PCPs lacked
consensus, the ‘strongly agree’ responses were com-
bined with the ‘agree’ responses and the ‘strongly dis-
agree’ responses were combined with the ‘disagree’
responses. Items with 50% or more of responses falling
into either the ‘agree’ or the ‘disagree’ category were
considered beliefs about which there was consensus.
Items for which neither the ‘agree’ nor the ‘disagree’
category contained 50% or more of the responses were
considered beliefs about which there was no consensus
and which may represent areas of confusion.
To identify associations between selected PCP
characteristics and item responses, a one-way analysis
of variance (ANOVA) was performed for each of the
30 items using the item as a dependent variable and
PCP characteristics as independent variables. Scheffe
post hoc tests were used to determine signiﬁcant dif-
ferences between independent variable groups.
Because a large number of statistical tests were per-
formed, alpha was set at < 0.01.
Results
PCP characteristics
The average age of respondents (n = 505) was
approximately 46 years; 81% were male and 62%
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cent of the PCPs were board certiﬁed in internal
medicine, and 78% reported seeing an average of
10–59 patients a week (Table 1).
Nearly, all PCPs indicated that their HbA1c goal
was £ 7% for patients with type 2 diabetes
< 50 years old (99%) or 50–70 years old (94%), and
81% indicated that their HbA1c goal was £ 7% for
patients > 70 years old.
Research question 1: shared beliefs
Table 2 presents the response distributions of belief
items for which > 50% of responses fell into the
‘agree’ or ‘disagree’ category. For the ﬁrst 13 items
listed, ‡ 66% of PCPs agreed with the statement,
indicating shared beliefs about the barrier that injec-
tion poses to patients’ acceptance of insulin (items 1,
3) and physician prescribing of insulin (item 6), the
importance of education to insulin initiation (item
2), the beneﬁts of insulin outweighing risks of hypo-
glycaemia (item 4) and weight gain (item 5), the
beneﬁt to patients of receiving insulin prior to the
development of complications (item 10), patient
fears prior to starting insulin (item 8), the physical
improvements in (item 9) and coping ability of
(items 7, 12) patients once they are on insulin, the
reluctance of patients on oral therapy to accept an
insulin prescription (item 11), and the initiation of
insulin as one of the most difﬁcult aspects of manag-
ing patients with type 2 diabetes (item 13).
At least 50% of PCPs agreed that most of their
patients on insulin are using their insulin as pre-
scribed (item 14) and are satisﬁed with their diabetes
therapy (item 16). More than half also agreed that
most of their patients on oral therapy would regard
insulin initiation as a personal failure (item 15).
The majority of PCPs disagreed that the follow-up
needed for most patients was too resource-intensive
for their staff (item 17) or that training in insulin
administration is too complicated for most patients
(item 18). The majority also disagreed that the risk
of weight gain made them reluctant to prescribe
insulin to patients with body mass index (BMI) ‡ 35
(item 19) and that the fear of side effects is the
greatest barrier to patients’ acceptance of insulin
therapy (item 20).
Research question 2: beliefs about which PCPs
lack consensus
Table 3 presents response distributions for the belief
items in which < 50% of responses fell into the ‘agree’
or ‘disagree’ category. Forty-four per cent of PCPs
agreed that the risk of hypoglycaemia would make
them reluctant to prescribe insulin for most patients
‡ 85 years old (item 1), 44% disagreed that most
patients on oral diabetes therapy would be less adher-
ent with insulin therapy, and 45% disagreed that they
should wait until patients on oral therapy have a beta
cell inadequacy to prescribe insulin (items 9, 10).
Response distributions for items 2 through 5 in
Table 3 show bimodal distributions (< 25% of the
responses were ‘neutral’, and remaining responses
were nearly equally divided between ‘agree’ and ‘dis-
agree’). The results indicate that PCPs lack consensus
that: most patients using insulin self-monitor their
blood glucose with sufﬁcient frequency, patients can
avoid insulin therapy by following their physicians’
recommendations, patients will need insulin therapy
regardless of treatment adherence, and the time
needed for training patients to use insulin is too
much for their staff.
Item response distributions for items 6 through 8 in
Table 3 show unimodal distributions (responses are
distributed approximately equally between ‘agree’,
‘neutral’ and ‘disagree’), suggesting that there is confu-
sion among PCPs about the metabolic effect of insulin.
Research question 3: associations between
beliefs and PCP characteristics
Gender
One signiﬁcant difference in beliefs by gender was
identiﬁed: Women agreed signiﬁcantly (p < 0.01)
Table 1 Primary care physician characteristics
glycaemic control treatment goals for different age
groups
Physician characteristics Total (n = 505)
Mean age, years (SD) 45.6 (8.7)
Male gender, n (%) 407 (81)
Years in practice, n (%)
3–5 years 55 (11)
6–10 years 139 (27)
11–15 years 84 (17)
16–30 years 215 (43)
More than 30 years 12 (2)
Primary care board certiﬁcation, n (%)
Internal medicine 262 (48)
Family practice 231 (50)
General practice 12 (2)
Number of patients with type 2 diabetes seen in an
average week, n (%)
10–25 172 (34)
26–59 221 (44)
60–99 60 (12)
100+ 52 (10)
Treatment goal (HbA1c £ 7%), n (%)
Younger than 50 years of age 498 (99)
51–69 years of age 474 (94)
More than 70 years of age 407 (81)
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of my patients on oral therapy would regard the ini-
tiation of insulin as a personal failure’.
Years of practice
Few PCPs in the study had practiced > 30 years, so
data from those PCPs were combined with data from
PCPs who had practiced 16–30 years for the one-way
ANOVA procedures. Post hoc analyses showed signif-
icant (p < 0.01) differences between categories of
years of practice for seven belief items (Table 4). In
general, PCPs with > 15 years experience agreed
more strongly than those with £ 15 years experience
that patients on insulin were able to cope with and
Table 2 Frequency distributions for items in which 50% or more primary care physicians (n = 505) ‘agreed’ or
‘disagreed’ with the statement in the order of descending agreement
Items
Response
Disagree to
strongly
disagree (%)
Neutral
(%)
Agree to
strongly
agree (%)
I believe…
1. …more of my patients would be willing to initiate insulin therapy if it were
not administered by injection
25 9 3
2. …for most of my patients, education is the key to the initiation of insulin 2 5 93
3. …for most of my patients, the injection route of administration is the
greatest barrier to their acceptance of insulin therapy
38 8 9
4. …for most of my patients, the beneﬁts of insulin therapy outweigh the risks
of hypoglycaemia
49 8 8
5. …for most of my patients, the beneﬁts of insulin therapy outweigh the risks
of weight gain
21 0 8 8
6. …primary care physicians might prescribe insulin more frequently if the
route of administration did not involve injections
71 0 8 3
7. …most of my patients using insulin are able to manage the demands of
insulin therapy
41 5 8 2
8. …most of my patients on oral diabetes therapy are afraid of insulin therapy 6 14 80
9. …most of my patients using insulin feel much better physically once they
become accustomed to using insulin therapy
42 0 7 6
10. …most patients would beneﬁt from receiving insulin therapy prior to the
development of diabetes complications
71 8 7 5
11. …most of my patients on oral diabetes therapy would be reluctant to
accept a prescription for insulin
11 18 72
12. …most of my patients ﬁnd the demands of insulin therapy to be less than
they expected
12 19 69
13. …the initiation of insulin is one of the most difﬁcult aspects of managing
my patients with type 2 diabetes
19 15 66
14. …most of my patients using insulin take their insulin as prescribed (i.e. are
adherent)
13 24 63
15. …most of my patients on oral diabetes therapy would regard the initiation
of insulin as a personal failure
21 26 53
16. …most of my patients using insulin are satisﬁed with their diabetes
therapy
19 28 53
17. …training in the proper administration and usage of insulin is too
complicated for most patients
58 22 20
18. …the follow-up needed for most of my patients on insulin is too
resource-intensive for my staff
53 22 25
19. …the risk of weight gain associated with insulin therapy makes me
reluctant to prescribe it for most of my patients with BMI ‡ 35
50 23 27
20. …for most of my patients, the fear of side effects (hypoglycaemia and⁄or
weight gain) is the greatest barrier to their acceptance of insulin therapy
50 24 26
BMI, body mass index.
Insulin initiation in patients with type 2 diabetes 863
ª 2008 Eli Lilly & Company
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, June 2008, 62, 6, 860–868Table 3 Frequency distributions for items in which < 50% of primary care physicians ‘agreed’ or ‘disagreed’ with the
statement in the order of descending agreement
Items
Response
Disagree to
strongly
disagree (%)
Neutral
(%)
Agree to
strongly
agree (%)
I believe…
1. …the risk of hypoglycaemia from insulin therapy makes me reluctant to
prescribe it for most of my patients ‡ 85 years of age
32 24 44
2. …most of my patients using insulin self-monitor their blood glucose with
sufﬁcient frequency
40 18 43
3. …training most of my patients in the proper administration and usage of
insulin is too time-consuming for my staff
38 21 40
4. …most patients would not need to go on insulin if they would follow their
physicians’ recommendations
36 24 40
5. …most patients will eventually need to go on insulin regardless of how well
they adhere to their treatment regimen
41 20 39
6. …insulin therapy has a beneﬁcial effect on insulin resistance 30 32 39
7. …increased levels of plasma insulin will increase the risk of a cardiovascular
event
32 33 35
8. …increasing insulin levels in obese patients will cause more insulin
resistance
31 38 31
9. …most patients do not need a prescription of insulin until they have a beta
cell inadequacy
44 25 31
10. …most of my patients on oral diabetes therapy would be less adherent
with insulin therapy
45 29 27
Table 4 Belief items with signiﬁcant (p < 0.01) one-way analysis procedures and at least one signiﬁcant post hoc test by
years of practice
Belief items
Years of practice, mean score (SD)
p-value
(ANOVA)
3–5
(n = 55)
6–10
(n = 139)
11–15
(n = 84)
>1 5
(n = 227)
I believe that…
…most of my patients using insulin feel much better physically
once they become accustomed to using insulin therapy
4.0* (0.6) 3.6 (0.7) 3.8 (0.6) 3.9 (0.7) 0.002
…the follow-up needed for most of my patients on insulin is
too resource-intensive for my staff
2.8 (1.0) 2.9 (1.0) 2.8 (1.1) 2.5  (0.9) 0.001
…training in the proper administration and usage of insulin is
too complicated for most patients
2.8 (0.9) 2.8 (0.9) 2.6 (1.0) 2.4  (0.8) < 0.001
…most of my patients using insulin are able to manage the
demands of insulin therapy
3.8 (0.7) 3.7 (0.6) 3.8 (0.5) 3.9  (0.5) 0.004
…most of my patients using insulin take their insulin as
prescribed (i.e. are adherent)
3.3 (0.9) 3.5 (0.7) 3.3 (0.8) 3.7 ,§ (0.7) < 0.001
…increased levels of plasma insulin will increase the risk of a
cardiovascular event
2.6* (1.0) 3.2 (0.9) 3.2 (0.9) 3.1 (0.9) 0.002
… increasing insulin levels in obese patients will cause more
insulin resistance
2.6*,– (1.0) 3.1 (0.8) 3.2 (0.9) 3.0 (0.9) < 0.001
*3–5 years are signiﬁcantly different from 6 to 10 years.  > 15 years are signiﬁcantly different from 6 to 10 years.  > 15 years are
signiﬁcantly different from 3 to 5 years. §> 15 years are signiﬁcantly different from 11 to 15 years. –3–5 years are signiﬁcantly differ-
ent from 11 to 15 years.
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respectively). In addition, the more experienced
group disagreed more strongly than the less experi-
enced group that training and follow-up for patients
on insulin were too resource-intensive or complex.
PCPs who had practiced 3–5 years disagreed more
strongly than one or more of the groups that had
practiced > 5 years that insulin has negative meta-
bolic effects.
Primary care certiﬁcation
For the one-way ANOVA procedures, data from gen-
eral practitioners were combined with data from
family practitioners because there were few general
practitioners in the study. One signiﬁcant (p < 0.01)
difference in beliefs was found between internists and
family⁄general practitioners: family⁄general practitio-
ners agreed more strongly that ‘…most patients
would not need to go on insulin if they would follow
their physicians’ recommendations’ (3.21 vs. 2.97).
Average number of patients with type 2
diabetes seen per week
Post hoc analyses showed signiﬁcant (p < 0.01) dif-
ferences between categories of number of patients
with type 2 diabetes seen per week for ﬁve belief
items (Table 5). Mean scores of PCPs who saw ‡ 100
such patients per week were signiﬁcantly different
from one or more of the categories of PCPs who saw
fewer such patients for all ﬁve items. PCPs seeing
‡ 100 such patients agreed more strongly that patient
fear of side effects was the greatest barrier to accep-
tance of insulin, the risk of weight gain made them
reluctant to use insulin in patients with BMI ‡ 35,
follow-up for patients on insulin is too resource-
intensive, training in proper use of insulin is too
complicated for most patients, and patients on oral
therapy would be less adherent with insulin therapy.
Discussion
This study indicates that while PCPs share some
beliefs about initiating insulin, there is a lack of con-
sensus about other aspects of insulin therapy. Most
shared beliefs fall into one of four categories: beneﬁts
of insulin therapy vs. risks, positive experiences of
patients on insulin, fears or concerns of patients still
on oral therapy, and the management of and training
for insulin use.
The majority of PCPs agreed that the beneﬁts of
using insulin to prevent or delay complications out-
weighed the risks of hypoglycaemia and weight gain
for most patients. However, there was less consensus
when the patient was severely obese or elderly. For
example, while the clear majority of PCPs agreed that
the beneﬁts of insulin outweighed the risks of hypo-
glycaemia for most patients, 44% agreed that the risk
of hypoglycaemia made them reluctant to prescribe
insulin to most patients who were ‡ 85 years old.
The risk of hypoglycaemia is greater in elderly
Table 5 Belief items with signiﬁcant (p < 0.01) one-way analysis procedures and at least one signiﬁcant post hoc test by
average number of patients with type 2 diabetes seen per week
Average number of patients with type 2
diabetes seen per week, mean score (SD)
p-value
(ANOVA)
10–25
(n = 172)
26–59
(n = 221)
60–99
(n = 60)
‡ 100
(n = 52)
I believe…
…for most of my patients, the fear of side effects
(hypoglycaemia and⁄or weight gain) is the greatest barrier to
their acceptance of insulin therapy
2.6 (0.9) 2.8 (1.0) 2.9 (1.1) 3.3*,  (1.0) < 0.001
…the risk of weight gain associated with insulin therapy
makes me reluctant to prescribe it for most of my patients
with BMI ‡ 35
2.7 (1.0) 2.6 (1.0) 2.9 (1.0) 3.2  (1.0) 0.001
…the follow-up needed for most of my patients on insulin is
too resource-intensive for my staff
2.6 (0.9) 2.6 (1.0) 2.8 (1.0) 3.2  (1.1) 0.001
…training in the proper administration and usage of insulin is
too complicated for most patients
2.5 (0.8) 2.5 (0.9) 2.8 (1.0) 3.0*,  (1.0) < 0.001
…most of my patients on oral diabetes therapy would be less
adherent with insulin therapy
2.7 (0.8) 2.8 (0.9) 2.9 (0.9) 3.2* (0.9) 0.002
BMI, body mass index. *100 or more patients are signiﬁcantly different from 10 to 25 patients.  100 or more patients are signiﬁcantly
different from 26 to 59 patients.
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and⁄or comorbidities (12) and impaired recovery
from hypoglycaemia (13,14). However, there is no
evidence to suggest that the treatment goal for other-
wise healthy elderly patients should differ from that
for younger patients (HbA1c £ 7%), and the PCPs in
this study agreed.
Most PCPs agreed that patients feel much better
after they have begun insulin and that patients can
manage the demands of insulin. Several studies have
conﬁrmed that patients, including elderly patients,
experience reduction in fatigue and increased feelings
of well-being when they begin insulin and that these
improvements are sustained over time (15–18). Most
PCPs also agreed that patients on insulin were satis-
ﬁed with their insulin therapy. Studies show that
patients on insulin, regardless of delivery mode (vial
and syringe, pen or inhalation), have high levels of
treatment satisfaction (19–21).
In a review of medication–adherence literature for
patients with type 2 diabetes, Rubin (22) concluded
that the adherence rate for oral antihyperglycaemic
medication was approximately 65–85%, and insulin
adherence may be slightly lower. In this study, nearly
two-thirds of PCPs believed that their insulin-using
patients were adherent, and only about a quarter of
PCPs agreed that their patients on oral therapy
would be less adherent to insulin therapy. Because
the potential beneﬁt patients receive from a treat-
ment can be largely dependent on their adherence
(22), further research is needed to determine whether
PCP perceptions of patient adherence to insulin are
accurate. Most PCPs agreed that patients on oral
therapy are afraid of insulin injections and that this
fear is a barrier to initiating insulin. PCPs were also
largely in agreement that patients on oral therapy
would be reluctant to initiate insulin and would have
feelings of personal failure. These general patient
concerns are well documented in the literature (3–5).
Nearly all PCPs agreed that for most patients, educa-
tion is the key to insulin initiation. However, Brun-
ton et al. (23) pointed out that this education is
usually given when diabetes has progressed to the
point that insulin is the only alternative for glucose
control. They further stressed the importance of
educating the patient at diagnosis about the disease
progression of diabetes and the inevitability of need-
ing insulin to maintain good glycaemic control,
rather than using insulin as a threat to motivate
patients.
Although Riddle (6) identiﬁed the complexity of
training patients in the proper use of insulin as a
contributing factor to its under-use, more than half
of the PCPs disagreed that training was too compli-
cated for patients or that follow-up was too
resource-intensive for their staff. However, there was
no consensus that the time needed for training in
the proper administration and usage of insulin was
too much for their staff. This is not surprising as
educational resources available to PCPs for insulin
initiation vary widely.
Primary care physicians also clearly lacked consen-
sus on whether patients on insulin performed self-
monitoring of blood glucose (SMBG) sufﬁciently for
appropriate insulin use. Appropriate SMBG fre-
quency varies according to insulin regimen: three or
four times daily is recommended for multiple injec-
tions, less frequent monitoring is needed for less
intensive therapy (24). However, SMBG in patients
with type 2 diabetes is often suboptimal (25). Reim-
bursement and resources for SMBG instruction may
be highly variable, and SMBG adds to the patient’s
‘hassle factor’. These issues may contribute to lack of
PCP consensus about patient SMBG sufﬁciency, but
patient fear of SMBG probably does not inﬂuence
this PCP belief (26).
Primary care physicians exhibited a clear dichot-
omy concerning whether adherence to a diabetes reg-
imen or following physician’s recommendations
would prevent patients with type 2 diabetes from
requiring insulin. Disagreement with the ﬁrst belief
and agreement with the second raise the question of
whether these PCPs respondents truly understood
the progressive nature of diabetes. Because of the
continuing decline in insulin secretion, within
6–10 years after diagnosis (sooner if the patient had
type 2 diabetes for years prior to diagnosis) as many
as 40–60% of patients with type 2 diabetes will need
insulin to maintain glycaemic control (27,28),
regardless of adherence to medication regimens
and⁄or following physician recommendations.
The three items with unimodal response distribu-
tion were based on Riddle’s (6) observations that
many physicians worry that insulin therapy results in
negative metabolic effects. The results of the United
Kingdom Prospective Diabetes Study (29) and the
Diabetes, Insulin-Glucose, And Myocardial Infarction
(30) studies led Riddle to conclude that there is
‘compelling evidence’ that insulin treatment is not
harmful with respect to cardiovascular disease and is
most likely beneﬁcial. A more recent retrospective
observational study using a national health-claims
database (31) reported the probability of a cardiovas-
cular event to be 34% less for patients with type 2
diabetes on insulin than for those not on insulin.
PCP beliefs about negative metabolic effects of insu-
lin may be based on lack of knowledge and indicate
a need for continuing medical education.
Two-thirds of the PCPs in this study agreed with
the statement ‘…the initiation of insulin is one of
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with type 2 diabetes’. When associations between
PCP characteristics and beliefs were examined, very
little difference was seen in beliefs by gender or type
of board certiﬁcation. However, PCP attitudes varied
by both years of practice and average number of
patients with type 2 diabetes seen per week. PCPs
with more years of practice had more positive atti-
tudes about patients on insulin than PCPs with less
experience, perhaps simply because of more long-
term experience with such patients. PCPs with the
least practice experience disagreed more strongly
than more experienced PCPs that insulin has nega-
tive metabolic effects. The beliefs of the least experi-
enced may reﬂect the fact that the ‘compelling
evidence’ mentioned by Riddle (6) has been incorpo-
rated into medical student and resident education.
Primary care physicians who treated greater num-
bers of patients with type 2 diabetes per week
appeared to be more risk-averse concerning insulin
initiation compared with those who saw fewer
patients, indicating that the diabetes care of many
patients with type 2 diabetes is being managed by
PCPs who have beliefs that suggest a reluctance to
initiate insulin therapy in such patients.
A limitation of this study is that the data were
self-reported and may differ from actual practice pat-
terns of the study participants. However, other work
has shown that physician attitudes are closely linked
to behaviour (32), leading us to assume that many
PCPs delay the prescribing of insulin to patients with
type 2 diabetes. Another limitation is that, according
to the AMA master ﬁle of 2000 (33), the percentage
of female physicians in primary care (deﬁned by
AMA as general and family practice, internal medi-
cine, obstetrics⁄gynaecology and paediatrics) in 2000
was approximately 34%. In our study, the percentage
of female PCPs was 20%. Therefore, the attitudes of
female PCPs may not have been sufﬁciently repre-
sented. Finally, another limitation is the survey
administration: This study is generalisable to only
those PCPs who have internet access and who would
volunteer for such a study. Nevertheless, sampling
was designed to ensure representation from all parts
of the country and equal representation of family
practitioners and internists.
Conclusions
The clear majority of PCPs in this study indicated
that their glycaemic control goal for patients of all
ages with type 2 diabetes is HbA1c £ 7%. Given that
insulin regimens are effective in reducing HbA1c lev-
els, the ﬁndings suggest that some PCPs have beliefs
about insulin that are barriers to attaining this gly-
caemic goal. Oral antihyperglycaemic therapies
potentially delay but do not halt the progressive nat-
ure of diabetes; thus insulin therapy eventually will
be needed by many patients with type 2 diabetes.
The lack of consensus about insulin initiation identi-
ﬁed in this study calls for continuing medical educa-
tion programmes that increase PCP knowledge about
diabetes and the physiological effects of insulin.
These programmes should provide PCPs, especially
those with large and challenging diabetes practices,
with strategies and tools for successfully initiating
insulin in patients with type 2 diabetes.
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